- Home
- PETS vs GRTS Comparison
PETS vs GRTS Comparison
Compare PETS & GRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- GRTS
- Stock Information
- Founded
- PETS 1996
- GRTS 2015
- Country
- PETS United States
- GRTS United States
- Employees
- PETS N/A
- GRTS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- GRTS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PETS Consumer Staples
- GRTS Health Care
- Exchange
- PETS Nasdaq
- GRTS Nasdaq
- Market Cap
- PETS 82.0M
- GRTS 22.4M
- IPO Year
- PETS N/A
- GRTS 2018
- Fundamental
- Price
- PETS $3.98
- GRTS $0.03
- Analyst Decision
- PETS Sell
- GRTS Hold
- Analyst Count
- PETS 2
- GRTS 4
- Target Price
- PETS $3.50
- GRTS $0.75
- AVG Volume (30 Days)
- PETS 174.8K
- GRTS 52.1M
- Earning Date
- PETS 10-28-2024
- GRTS 11-06-2024
- Dividend Yield
- PETS 28.95%
- GRTS N/A
- EPS Growth
- PETS N/A
- GRTS N/A
- EPS
- PETS N/A
- GRTS N/A
- Revenue
- PETS $270,772,000.00
- GRTS $14,610,000.00
- Revenue This Year
- PETS N/A
- GRTS N/A
- Revenue Next Year
- PETS $3.27
- GRTS $90.97
- P/E Ratio
- PETS N/A
- GRTS N/A
- Revenue Growth
- PETS 2.26
- GRTS 25.09
- 52 Week Low
- PETS $2.90
- GRTS $0.03
- 52 Week High
- PETS $10.53
- GRTS $3.17
- Technical
- Relative Strength Index (RSI)
- PETS 54.93
- GRTS 18.39
- Support Level
- PETS $3.89
- GRTS $0.18
- Resistance Level
- PETS $4.22
- GRTS $0.23
- Average True Range (ATR)
- PETS 0.20
- GRTS 0.02
- MACD
- PETS -0.02
- GRTS -0.01
- Stochastic Oscillator
- PETS 47.37
- GRTS 0.00
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About GRTS Gritstone bio Inc.
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.